［1］COLEMAN R E. Skeletal complications of malignancy.Cancer，1997，80（Supplement 8）：1588-1594.

［2］MACEDO F，LADEIRA K，PINHO F，et al. Bone Metastases：An Overview. Oncol Rev，2017，11（1）：321.

［3］VON MOOS R，BODY JJ，EGERDIE B，et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer，2016，24（3）：1327-1337.

［4］SATHIAKUMAR N，DELZELL E，MORRISEY M A，et al.Mortality following bone metastasis and skeletal-related events among women with breast cancer：a population-based analysis of U.S. Medicare beneficiaries，1999-2006.Breast Cancer Res Treat，2012，131（1）：231-238.

［5］SATHIAKUMAR N，DELZELL E，MORRISEY M A，et al.Mortality following bone metastasis and skeletal-related events among men with prostate cancer：a population-based analysis of US Medicare beneficiaries，1999-2006.Prostate Cancer P D，2011，14（2）：177-183.

［6］LECOUVET F E，TALBOT J N，MESSIOU C，et al. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques：a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer，2014，50（15）：2519-2531.

［7］RYBAK L D，ROSENTHAL D I. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med，2001，45（1）：53-64.

［8］D’ELIA G，CARACCHINI G，CAVALLI L，et al. Bone fragility and imaging techniques. Clin Cases Miner Bone Metab，2009，6（3）：234-246.

［9］SAHIN E，ZINCIRKESER S，AKCAN A B，et al. Is（99m）Tc-MDP whole body bone scintigraphy adjuvant to（18）F-FDGPET for the detection of skeletal metastases？J BUON，2014，19（1）：291-296.

［10］AK I，SIVRIKOZ M C，ENTOK E，et al. Discordant findings in patients with non-small-cell lung cancer：absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg，2010，37（4）：792-796.

［11］DE LA PIEDRA C，ALCARAZ A，BELLMUNT J，et al.Usefulness of bone turnover markers as predictors of mortality risk，disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid：TUGAMO study. Brit J Cancer，2013，108（12）：2565-2572.

［12］VALLATH N，RAJAGOPAL M R，PERERA S，et al. Access to pain relief and essential opioids in the WHO South-East Asia Region：challenges in implementing drug reforms.WHO South East Asia J Public Health 2018；7（2）：67-72.

［13］ROSS J R，SAUNDERS Y，EDMONDS P M，et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ，2003，327（7413）：469.

［14］CLEMONS M，DRANITSARIS G，OOI W，et al. A phaseⅡ trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event（SRE）or progressive bone metastases（BM）despite standard bisphosphonate（BP）therapy. Breast Cancer Res Treat，2008，108（1）：79-85.

［15］ZAROGOULIDIS K，BOUTSIKOU E，ZAROGOULIDIS P，et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastases. Int J Cancer，2009，125（7）：1705-1709.

［16］GRANT M，MLINERITSCH B，SCHIPPINGER W，et al.Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med，2009，360（7）：679-691.

［17］AFT R，NAUGHTON M，TRINKAUS K，et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer：an open label，randomized，phase 2 trial. Lancet Oncol，2010，11（5）：421-428.

［18］WONG M H，STOCKLER M R，PAVLAKIS N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev，2012，15（2）：CD003474.

［19］GUARNERI V，DONATI S，NICOLINI M，et al. Renal safety and efficacy of i. v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist，2005，10（10）：842-848.

［20］CLEMONS M J，DRANITSARIS G，OOI W S，et al. PhaseⅡ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol，2006，24（30）：4895-4900.

［21］VAN DEN WYNGAERT T，DELFORGE M，DOYEN C，et al. Prospective observational study of treatment pattern，effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Support Care Cancer，2013，21（12）：3483-3490.

［22］DE LEMOS M L，TAYLOR S C，BARNETT J B，et al. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients：comparison between clinical trials and population-based database. J Oncol Pharm Pract，2006，12（4）：193-199.

［23］潘小云.阿仑膦酸钠致眼巩膜炎1例.江西中医药，2009，40（2）：61.

［24］BAMIAS A，KASTRITIS E，BAMIA C，et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates：incidence and risk factors. J Clin Oncol，2005，23（34）：8580-8587.

［25］CHOW E，HARRIS K，FAN G，et al. Palliative radiotherapy trials for bone metastases：a systematic review. J Clin Oncol，2007，25（11）：1423-1436.

［26］FORO ARNALOT P，FONTANALS A V，GALCERÁN J C，et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases：30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol，2008，89（2）：150-155.

［27］LUTZ S，BERK L，CHANG E，et al. American Society for Radiation Oncology（ASTRO）. Palliative radiotherapy for bone metastases：an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys，2011，79（4）：965-976.

［28］REDMOND K J，ROBERTSON S，LO S S，et al. Consensus contouring guidelines for postoperative stereotactic body radiation therapy for metastatic solid tumor malignancies to the spine. Int J Radiat Oncol Biol Phys，2017，97（1）：64-74.

［29］JHAVERI P，TEH B S，BLOCH C，et al. Stereotactic body radiotherapy in the management of painful bone metastases.Oncology，2008，22（7）：782-788.

［30］BENEDICT S H，YENICE K M，FOLLOWILL D，et al.Stereotactic body radiation therapy：The report of AAPM Task Group 101.Med Phys，2010，37（8）：4078-4101.

［31］FURUBAYASHI N，NEGISHI T，URA S，et al. Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis. Mol Clin Oncol，2015，3（1）：257-263.

［32］YAN B，MENG X，WANG X，et al. Complete regression of advanced prostate cancer for ten years：A case report and review of the literature. Oncol Lett，2013，6（2）：590-594.

［33］YAMADA K，YOSHIMURA M，KAISE H，et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med，2012，3（2）：226-230.

［34］KARASAWA K. Cancer therapy using unsealed radioisotopesthe present and future. Gan To Kagaku Ryoho，2014，41（13）：2555-2558.

［35］费菲.我国骨肿瘤循证临床诊疗指南2015最新解读（中）.中国医药科学，2015，5（13）：5-6.

［36］费菲.我国骨肿瘤循证临床诊疗指南2015最新解读（下）.中国医药科学，2015，5（16）：5-6.

［37］PETERS S，MEYLAN E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol，2013，25（2）：137-144.

［38］FIZAZI K，CARDUCCI M，SMITH M，et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer：a randomised，double-blind study. Lancet，2011，377（9768）：813-822.

［39］EMERY J G，MCDONNELL P，BURKE M B，et al. Osteoprotegerin is a receptor for the cytotoxic ligand trail. J Biol Chem，1998，273（23）：14363-14367.

［40］RACHNER T D，KHOSLA S，HOFBAUER L C. Osteoporosis：now and the future. Lancet，2011，377（9773）：1276-1287.

［41］PARKER C，NILSSON S，HEINRICH D，et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med，2013，369（3）：213-223.

［42］LI BT，WONG MH，PAVLAKIS N. Treatment and prevention of bone metastases from breast cancer：A comprehensive review of evidence for clinical practice. J Clin Med，2014，3（1）：1-24.

［43］中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南（2017）.中华骨质疏松和骨矿盐疾病杂志，2017，20（5）：413-443.

［44］DORIA C，LEALI PT，SOLLA F，et al. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients？A prospective randomized multicenter international study. Clin Cases Miner Bone Metab，2016，13（3）：195-199.

［45］程晓光.国际临床骨密度学会共识文件（2005年版）.中国骨质疏松杂志，2006，12（2）：205-209.

［46］GENANT H K，WU C Y，VAN KUIJK C，et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res，1993，8（9）：1137-1148.

［47］GUISE TA. Bone loss and fracture risk associated with cancer therapy. Oncologist，2006，11（10）：1121-1131.

［48］中国营养学会.中国居民膳食营养素参考摄入量速查手册.北京：中国标准出版社，2014.

［49］HOLICK MF. Vitamin D deficiency. N Engl J Med，2007，357（3）：266-281.

［50］SMITH H，ANDERSON F，RAPHAEL H，et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based，randomized，doubleblind，placebo-controlled trial. Rheumatology（Oxford），2007，46（12）：1852-1857.

［51］RUSSELL R G，WATTS N B，EBETINO F H，et al. Mechanisms of action of bisphosphonates：similarities and differences and their potential influence on clinical efficacy. Osteoporos Int，2008，19（6）：733-759.

［52］朱汉民，廖二元.鲑鱼降钙素专家讨论会纪实.中华骨质疏松和骨矿盐疾病杂志，2013，6（4）：370-372.

［53］COSMAN F，DE BEUR S J，LEBOFF M S，et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int，2014，25（10）：2359-2381.

［54］PALACIOS S，MEJIA A. Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. Climacteric，2015，18（4）：453-455.

［55］CUMMINGS S R，SAN MARTIN J，MCCLUNG M R，et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med，2009，361（8）：756-765.